Skip to main content

Table 7 Means and SD for all patients and controls and separated into women and men for the State aR total scale and subscales (State rest/activity, State orthostatic-circulatory, State thermosweating and State digestive regulation) and Trait aR total and subscales (Trait rest/activity regulation, Trait orthostatic-circulatory, Trait digestive regulation).

From: Validation of the state version questionnaire on autonomic regulation (state-aR) for cancer patients

 

S-aR Total scale

S-Rest-activitiy aR

S-Orthostatic-circulatory aR

S-Thermo-sweating aR

S-Digestive aR

T-aR Total scale

T-Rest-activity aR

T-Orthostatic-circulatory aR

T-Digestive aR

Study 1

         

Patients

         

Mean all

65.86

27.81

17.12

10.61

10.30

41.49

17.85

1 6.57

7.00

(SD)

(9.20)

(5.11)

(2.83)

(3.21)

(2.86)

(5.70)

(3.51)

(2.72)

(1.53)

Mean women

65.24

27.51

17.00

10.07

10.63

40.54

17.59

16.00

6.95

(SD)

(8-77)

(4.94)

(2.97)

(2.95)

(2.97)

(5.54)

(3.37)

(2.67)

(1.49)

Mean men

67.44

28.56

17.44

10.56

10.87

44. 14

18.53

18.07

7.12

(SD)

(10.36)

(5.64)

(2.68)

(3.86)

(2.63)

(5.48)

(3.87)

(2.34)

(1.67)

Control

73.65

32.96

17.70

11.51

11.47

43.36

19.55

16.41

7.51

Mean all (SD)

(7.56)

(4.31)

(2.54)

(2.73)

(2.31)

(4.65)

(2.87)

(2.50)

(1.48)

Mean women

73.27

32.39

17.78

11.37

11.73

42.45

18.90

16.03

7.59

(SD)

(7.49)

(4.55)

(2.66)

(2.84)

(1.98)

(4.63)

(2.99)

(2.50)

(1.32)

Mean men

74.62

34.44

17.50

10.81

11.87

42.45

18.90

16.03

7.59

(SD)

(7.89)

(3.31)

(2.28)

(2.97)

(2.47)

(4.63)

(2.99)

(2.50)

(1.32)

p-value

< 0.001

< 0.001

0.21

0.14

0.015

0.090

0.006

0.75

0.029

Patients vs Control*

         

Study 2

         

Breast cancer

70.29

30.76

17.18

10.65

11.65

41.53

17.56

16.62

7.35

group 1 T0

(6.72)

(3.47)

(2.43)

(2.42)

(1.73)

(4.41)

(3.31)

(1.59)

(1.06)

Breast cancer

67.50

28.94

17.19

10.81

10.50

40.25

17.50

16.06

6.76

group 1 T1

(10.59)

(6.16)

(3.51)

(2.74)

(2.66)

(6.54)

(3.60)

(3.11)

(1.60)

Breast cancer

67.65

29.75

16.65

10.53

10.94

41.12

17.41

16.47

7.23

group 1 T2

(10.09)

(5.93)

(3.82)

(3.20)

(2.68)

(6.53)

(3.69)

(2.87)

(1.39)

Colorectal cancer

73.39

31.27

18.38

12.44

11.09

43.83

19.08

17.25

7.38

T0

(8.62)

(5.24)

(2.28)

(2.48)

(2.88)

(4.13)

(2.86)

(1.77)

(1.64)

Colorectal cancer

69.87

28.46

17.46

12.42

11.58

43.29

18.81

17.04

7.57

T1

(12.11)

(6.78)

(3.39)

(3.30)

(2.19)

(5.22)

(3.47)

(2.16)

(1.34)

Colorectal cancer

71.25

30.20

16.91

12.36

11.74

43.67

18.95

17.04

7.71

T2

(10.04)

(5.99)

(3.45)

(1.91)

(1.42)

(5.13)

(3.42)

(2.07)

(1.00)

p-value T0 vs T1 **

0.010

0.001

0.243

0.413

0.325

0.079

0.226

0.061

0.306

p-value T1 vs T2**

0.484

0.061

0.106

0.395

0.114

0.243

0.432

0.222

0.119

  1. Significant results are shown in bold.
  2. *Exact U-Test (2-side) between Cancer group and healthy controls,
  3. ** Exact Wilcoxon-Test (1-side) used for pooled breast cancer and colorectal cancer and tests T0 (before chemotherapy) vs. T1 (1-5 days after third chemotherapy cycle) and T1 vs, T2 (4-8 weeks after the end of chemotherapy).
  4. Significant differences (p < 0.05) are shown in bold.